University of Leipzig
University of Leipzig is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
A phase II study evaluating the efficacy and safety of imetelstat in patients with HR myelodysplastic syndromes or AML failing HMA-based therapy
Sponsor Gcp-Service International West GmbH
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The interim analysis of the first 21 evaluable patients identified no primary-endpoint responders; the dosing schedule was amended and subsequent efficacy analyses continued exploratorily.
- High early discontinuation and death rates resulted in limited evaluable efficacy data, and substantial missing data added uncertainty to the results.
- Delayed serious-adverse-event reporting occurred because several sites were uncertain whether progression to AML met serious-adverse-event reporting criteria.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)
Sponsor Takeda Development Center Americas Inc.
- Start (EU)
- Latest update
- Estimated end
A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based therapy.
Sponsor Gcp-Service International West GmbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for University of Leipzig?
The 2026-10-09 snapshot links University of Leipzig to 3 distinct CTIS trials. Recorded services include Laboratory services, Medical expertise. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for University of Leipzig?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to University of Leipzig conducted?
The linked trials record locations in 11 countries, including Germany, France, Bulgaria, Czechia, Spain. These are trial locations, not confirmed office locations or countries where University of Leipzig delivered services.
What can this page tell me about University of Leipzig's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under University of Leipzig. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- University of Leipzig